ArticleScientific reports2026
Prevalence of hearing loss and other ear disorders among patients with hepatitis B infection: a nationwide retrospective Polish cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports from Asian populations have suggested that chronic hepatitis B virus (HBV) infection may predispose patients to hearing impairment, particularly sudden sensorineural hearing loss, yet evidence from Europe has been lacking. To address this gap, we conducted a nationwide, retrospective analysis of the prevalence of ear and hearing disorders among patients hospitalized with HBV infection in Poland between 2012 and 2023, using the national hospital discharge database. Hospital records with ICD-10 codes for acute or chronic HBV infection were examined, and cases with concomitant ear or hearing disorders were identified. In total, 80,181 HBV-related hospitalizations were recorded, of which 36.6% represented first-time admissions, while the remainder were repeat hospitalizations. Diagnoses of hearing loss were rare, occurring in only 0.05% of first-time and 0.04% of all hospitalizations, and all affected patients were adults. Hearing loss diagnoses, including those encompassing both conductive and sensorineural forms, were exceptionally uncommon. Notably, conditions most frequently discussed in the context of HBV, such as sensorineural hearing loss, were rare and showed no tendency to recur across repeated admissions. Importantly, the prevalence of hearing disorders in this HBV-infected cohort was substantially lower than that reported for the general population, suggesting no increased prevalence of auditory disorders among patients with HBV infection in this setting. These findings indicate that, in contrast to observations from parts of Asia, chronic HBV infection is not associated with an increased prevalence of hearing impairment in this European population. Discrepancies with Asian studies likely reflect multiple regional factors, including differences in HBV genotype distribution, disease characteristics, healthcare practices, and host or environmental influences, rather than genotype alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.